U.S. markets closed
  • S&P 500

    3,693.23
    -64.76 (-1.72%)
     
  • Dow 30

    29,590.41
    -486.27 (-1.62%)
     
  • Nasdaq

    10,867.93
    -198.88 (-1.80%)
     
  • Russell 2000

    1,679.59
    -42.72 (-2.48%)
     
  • Crude Oil

    79.43
    -4.06 (-4.86%)
     
  • Gold

    1,651.70
    -29.40 (-1.75%)
     
  • Silver

    18.83
    -0.78 (-3.99%)
     
  • EUR/USD

    0.9693
    -0.0145 (-1.47%)
     
  • 10-Yr Bond

    3.6970
    -0.0110 (-0.30%)
     
  • GBP/USD

    1.0857
    -0.0398 (-3.54%)
     
  • USD/JPY

    143.3300
    +0.9950 (+0.70%)
     
  • BTC-USD

    18,922.57
    -172.93 (-0.91%)
     
  • CMC Crypto 200

    434.61
    -9.92 (-2.23%)
     
  • FTSE 100

    7,018.60
    -140.92 (-1.97%)
     
  • Nikkei 225

    27,153.83
    -159.30 (-0.58%)
     

EMA's Advisory Committee Backs Approval For AstraZeneca's Targeted Breast Cancer Therapies

·1 min read
  • The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of Enhertu (trastuzumab deruxtecan) as monotherapy for unresectable or metastatic HER2-positive breast cancer patients who have received one or more prior anti-HER2-based regimens.

  • Enhertu is being jointly developed and commercialized by AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSNKY).

  • Also Read: AstraZeneca-Daiichi Breast Cancer Drug Cuts Disease Progression Or Death Risk By Almost 50%.

  • The positive opinion is based on results from the DESTINY-Breast03 Phase 3 trial, in which Enhertu reduced the risk of disease progression or death by 72% versus trastuzumab emtansine.

  • CHMP also backed Lynparza (olaparib) as monotherapy or combined with endocrine therapy as adjuvant treatment of HER2-negative high-risk early breast cancer with germline BRCA1/2 mutations (gBRCAm) in previously treated patients with neoadjuvant or adjuvant chemotherapy.

  • Lynparza demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival, reducing the risk of invasive breast cancer recurrences, new cancers, or death by 42% versus placebo.

  • Lynparza is jointly developed and commercialized by AstraZeneca and Merck & Co Inc (NYSE: MRK).

  • Price Action: AZN shares are down 0.48% at $66.58 during the premarket session on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.